Project overview & milestone plan
The well validated research of Coegin Pharma has demonstrated that the cPLA₂α enzyme is a relevant therapeutic target for a number of cancers and inflammatory diseases, including actinic keratosis, basal cell carcinoma, leukemia, triple-negative breast cancer and chronic kidney disease.
The Company has previously established proof-of-conceptin psoriasis, which is a robust validation of the mechanism of action. The company’s development projects all derive from the same unique mechanism of action, and the Board of Directors’ assessment is that Coegin Pharma holds unique potential to develop first-in-class pharmaceuticals for the treatment of several serious diseases where current treatment options are insufficient.
|Project/Indication||Candidate||Route of administration||2021||2022||2023|
|Actinic keratosis||AVX001||Topical||Phase I/II|
|Leukemia/breast cancer||Not disclosed||Systemic||Pre-clinical||Pre-clinical||Phase I|
|Chronic kidney disease||Not disclosed||Systemic||Pre-clinical||Pre-clinical||Phase I|
Major milestones 2021 – 2022
Actinic keratosis (Phase I/II)
|Basal cell carcinoma (Phase IIa)||Cancer (Phase I ready)||Chronic kidney disease (Phase I ready)||Spinout|